In this interview, at ESMO 2018, Dr Raffaele Califano talks to touchONCOLOGY about epidermal growth factor receptor (EGFR) expression in non-small cell lung cancer (NSCLC). He explains the importance of detecting EGFR activity prior to treatment in order to treat the patient effectively. Dr Califano also discusses the results from several recent trials including the phase III FLAURA trial in mechanisms of acquired resistance, a phase II study of nazartinib in patients with treatment-naive EGFR-mutant NSCLC, and the phase Ib study in teliso-V monotherapy and in combination with erlotinib. Finally, he looks to the future of mechanisms of resistance and how best to tackle them.
1. What incidence of patients with non-small cell lung cancer (NSCLC) express EGFR, and how do management strategies differ in these patients? (0:11)
2. What new data around EGFR-mutated NSCLC is being presented at this year’s ESMO congress, and what are the implications for clinical practice? (0:52)
3. What are the next steps in this field of research? (5:56)
Speaker disclosures: Raffaele Califano has nothing to disclose in relation to this interview.
Filmed at the European Society for Medical Oncology (ESMO) 2018 Congress, Munich, Germany, 19–23 October 2018.
Share this Video
Related Videos In Lung Cancer
Paula Ugalde, WCLC 2021: Screening, Incidental Nodules, and Adjuvant Therapy for Early-Stage Lung Cancer
touchONCOLOGY joins Dr Paula Ugalde (Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA) at WCLC 2021 to discuss her presentation on screening, incidental nodules and adjuvant therapy for early-stage lung cancer. Questions 1. Early detection of lung cancer improves disease outcomes – when and in which patients do you perform screening? (00:15-00:46) 2. […]
Antoinette Wozniak, WCLC 2021: Important Recent Developments in the Diagnosis and Management of Small Cell Lung Cancer
touchONCOLOGY joins Prof Antoinette Wozniak (UPMC Hillman Cancer Center, Pittsburgh, PA, USA) at WCLC 2021 to discuss the challenges of treating small cell lung cancer and the most important recent advances. Questions 1. Please can you outline the current prognosis for patients with small cell lung cancer (SCLC)? (00:26-02:37) 2. In your opinion, what are […]
Antoinette Wozniak, WCLC 2021: Highlights of the digital 2021 conference
touchONCOLOGY joins Editorial Board Member Prof Antoinette Wozniak (UPMC Hillman Cancer Center, Pittsburgh, PA, USA) at WCLC 2021 to discuss her highlights of the conference this year. Question What have been your particular highlights of the World Conference on Lung Cancer 2021? Disclosures: Antoinette Wozniak has no financial or non-financial conflicts of interest to declare […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!